Guillain-Barr é Syndrome following a series of novel therapies adapting the gold-standard in the era of immune priming
Over the past two decades, there has been a fundamental shift away from traditional cytotoxic chemotherapy towards the identification, and subsequent suppression of specific oncogenes. Immunotherapy and targeted therapy prime the immune system, potentially leading to deleterious side effects. The following case of Guillain-Barr é Syndrome (GBS) emphasizes the importance of considering every agent when iatrogenic toxicity is suspected. We underline the possibility of immune priming by checkpoint inhibitors.
Source: Journal of Neuroimmunology - Category: Allergy & Immunology Authors: Catherine Maurice, Leila Khoja, Erin Morgan, Warren P. Mason, Hans Katzberg, Austin M. Pereira, Amanda Pereira, Marcus Butler Tags: Short Communication Source Type: research
More News: Allergy & Immunology | Brain | Chemotherapy | Guillain-Barr Syndrome | Immunotherapy | Neurology | Toxicology